Indication
Human Papillomavirus-18 Positive
1 clinical trial
1 product
Clinical trial
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive IndividualsStatus: Active (not recruiting), Estimated PCD: 2029-09-20
Product
VGX-3100